At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BIAF bioAffinity Technologies, Inc.
Pre-Mkt 06-08 07:16:52 EDT
1.73
-0.15
-7.98%
盘前1.70
-0.03-1.67%
07:16 EDT
High2.05Low1.72Vol229.50K
Open1.86D1 Closing1.88Amplitude17.55%
Mkt Cap7.78MTradable Cap5.88MTotal Shares4.50M
T/O431.85KT/O Rate6.75%Tradable Shares3.40M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

bioAffinity to present CyPath Lung test in Society for Advanced Bronchoscopy webinar
Reuters  ·  06-02
bioAffinity to present CyPath Lung test in Society for Advanced Bronchoscopy webinar
BioAffinity Technologies announces notification of Mexico patent allowance
TIPRANKS  ·  05-27
BioAffinity Technologies announces notification of Mexico patent allowance
bioAffinity Technologies says Mexico allows patent covering CyPath Lung cancer detection methods
Reuters  ·  05-27
bioAffinity Technologies says Mexico allows patent covering CyPath Lung cancer detection methods
bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using Cypath® Lung Technology
THOMSON REUTERS  ·  05-27
bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using Cypath® Lung Technology
bioAffinity reports April CyPath Lung unit sales jump nearly 300% year over year
Reuters  ·  05-12
bioAffinity reports April CyPath Lung unit sales jump nearly 300% year over year
bioAffinity Technologies Q1 EPS $(0.81) Beats $(2.70) Estimate, Sales $1.352M Miss $1.553M Estimate
Benzinga  ·  05-08
bioAffinity Technologies Q1 EPS $(0.81) Beats $(2.70) Estimate, Sales $1.352M Miss $1.553M Estimate
bioAffinity Technologies Inc - Total Consolidated Revenue Decreases 27% to $1.4 Mln in Q1 2026
THOMSON REUTERS  ·  05-08
bioAffinity Technologies Inc - Total Consolidated Revenue Decreases 27% to $1.4 Mln in Q1 2026
bioAffinity Technologies Inc - Q1 2026 Net Loss $3.6 Mln or $0.81 per Share
THOMSON REUTERS  ·  05-08
bioAffinity Technologies Inc - Q1 2026 Net Loss $3.6 Mln or $0.81 per Share
bioAffinity Q1 FY26 net loss widens to $3.6 million; revenue drops 27% to $1.4 million
Reuters  ·  05-08
bioAffinity Q1 FY26 net loss widens to $3.6 million; revenue drops 27% to $1.4 million
Press Release: bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath(R) Lung
Dow Jones  ·  05-08
Press Release: bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath(R) Lung
bioAffinity Technologies shareholders approve equity plan share reserve increase to 1 million
Reuters  ·  05-01
bioAffinity Technologies shareholders approve equity plan share reserve increase to 1 million
BioAffinity Technologies files to sell 497,483 shares of common stock for holder
TIPRANKS  ·  05-01
BioAffinity Technologies files to sell 497,483 shares of common stock for holder
BioAffinity Technologies launches new study to expand use of CyPath lung tech
TIPRANKS  ·  04-28
BioAffinity Technologies launches new study to expand use of CyPath lung tech
bioAffinity launches pilot study with Brooke Army Medical Center for asthma, COPD tests
Reuters  ·  04-28
bioAffinity launches pilot study with Brooke Army Medical Center for asthma, COPD tests
bioAffinity releases case study on CyPath Lung test guiding nodule follow-up imaging
Reuters  ·  04-14
bioAffinity releases case study on CyPath Lung test guiding nodule follow-up imaging
bioAffinity to present CyPath Lung test at Cleveland Clinic early lung cancer symposium
Reuters  ·  04-07
bioAffinity to present CyPath Lung test at Cleveland Clinic early lung cancer symposium
BioAffinity’s CyPath Lung Test unit sales surged 146% y/y in Q1
TIPRANKS  ·  04-01
BioAffinity’s CyPath Lung Test unit sales surged 146% y/y in Q1
bioAffinity CyPath Lung unit sales jump 146% in Q1 2026
Reuters  ·  04-01
bioAffinity CyPath Lung unit sales jump 146% in Q1 2026
What's Going On With bioAffinity Technologies Stock Wednesday?
Benzinga  ·  03-25
What's Going On With bioAffinity Technologies Stock Wednesday?
bioAffinity Technologies to host live virtual physician roundtable; CyPath Lung adoption grows in pulmonary practice discussion
Reuters  ·  03-25
bioAffinity Technologies to host live virtual physician roundtable; CyPath Lung adoption grows in pulmonary practice discussion

Introduction

Company Name.
bioAffinity Technologies, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.
Issue price:
--